代谢综合征与房颤患者非血栓栓塞性心脏不良结局的关联
该前瞻性观察研究纳入843例无明确冠心病的房颤患者,按NCEP标准定义代谢综合征,随访5年复合MACE包括心肌梗死、冠脉血运重建和心源性死亡。代谢综合征患者占35.8%,其MACE风险独立增加(aHR 1.98),心肌梗死、血运重建和心源性死亡风险亦显著升高,倾向评分调整后关联仍显著。
要点
- 无明确冠心病的房颤患者中代谢综合征患病率达35.8%。
- 代谢综合征独立增加5年MACE风险(aHR 1.98)。
- 代谢综合征与心源性死亡风险升高相关(aHR 2.59)。
核心结论
- 代谢综合征在无明确冠心病的房颤患者中常见,并独立增加MACE风险,包括心肌梗死、冠脉血运重建和心源性死亡。
研究设计与样本
- 前瞻性观察研究,纳入843例无明确冠心病的房颤患者,平均年龄62.5±12.1岁,女性占38.6%。
- 代谢综合征按美国国家胆固醇教育计划(NCEP)标准定义。
- 5年复合MACE包括心肌梗死、冠脉血运重建和心源性死亡。
主要发现
- 代谢综合征患者302例(35.8%)。
- 5年随访期间118例(14.0%)发生MACE,年发生率为2.80%。
- 代谢综合征对MACE的多变量校正风险比(aHR)为1.98(95%CI 1.23-3.16;P=0.004)。
- 代谢综合征对心肌梗死的aHR为2.00(95%CI 1.69-5.11;P<0.001),对冠脉血运重建的aHR为2.33(95%CI 1.40-3.87;P=0.001),对心源性死亡的aHR为2.59(95%CI 1.25-5.33;P=0.011)。
- 倾向评分调整后,代谢综合征与MACE(PS-aHR 1.87;95%CI 1.21-3.01;P=0.012)、心肌梗死(PS-aHR 1.72;95%CI 1.54-5.00;P=0.008)、血运重建(PS-aHR 2.18;95%CI 1.69-3.11;P=0.015)和心源性死亡(PS-aHR 2.27;95%CI 1.14-5.11;P=0.023)的关联仍显著。
临床怎么用
- 对无明确冠心病的房颤患者应评估代谢综合征,以识别非血栓栓塞性心脏不良事件高危人群。
- 代谢综合征的预防和治疗可能减少房颤患者的非血栓栓塞性并发症负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Evidence suggests an excess risk of non-thromboembolic major adverse cardiac events (MACE) associated with atrial fibrillation (AF), particularly in individuals free of overt coronary artery disease (CAD). Metabolic syndrome (MetS) increases cardiovascular risk in the general population, but less is known how it influences outcomes in AF patients. We aimed to assess whether MetS affects the risk of MACE in AF patients without overt CAD. METHODS AND RESULTS: This prospective, observational study enrolled 843 AF patients (mean-age, 62.5 ± 12.1 years, 38.6% female) without overt CAD. Metabolic syndrome was defined according to the National Cholesterol Education Program. The 5-year composite MACE included myocardial infarction (MI), coronary revascularization, and cardiac death. Metabolic syndrome was present in 302 (35.8%) patients. At 5-year follow-up, 118 (14.0%) patients experienced MACE (2.80%/year). Metabolic syndrome conferred a multivariable adjusted hazard ratio (aHR) of 1.98 for MACE [95% confidence interval (CI), 1.23-3.16; P = 0.004], and for individual outcomes: MI (aHR, 2.00; 95% CI, 1.69-5.11; P < 0.001), revascularization (aHR, 2.33; 95% CI, 1.40-3.87; P = 0.001), and cardiac death (aHR, 2.59; 95% CI, 1.25-5.33; P = 0.011). Following the propensity score (PS)-adjustment for MetS, the association between MetS and MACE (PS-aHR, 1.87; 95% CI, 1.21-3.01; P = 0.012), MI (PS-aHR, 1.72; 95% CI, 1.54-5.00; P = 0.008), revascularization (PS-aHR, 2.18; 95% CI, 1.69-3.11; P = 0.015), and cardiac death (PS-aHR, 2.27; 95% CI, 1.14-5.11; P = 0.023) remained significant. CONCLUSION: Metabolic syndrome is common in AF patients without overt CAD, and confers an independent, increased risk of MACE, including MI, coronary revascularization, and cardiac death. Given its prognostic implications, prevention and treatment of MetS may reduce the burden of non-thromboembolic complications in AF.
引用
- Polovina M, Hindricks G, Maggioni A, et al. Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. Eur Heart J. 2018. PMID: 30101326. doi:10.1093/eurheartj/ehy446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。